HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis
- 13 August 2007
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 22 (7) , 463-467
Abstract
The 5HT2C receptor (HTR2C) has been hypothesized to represent an important modulator in feeding behavior. Evidence was based on the observation that knock‐out mice for the HTR2C receptor gene develop obesity and that many antipsychotics (AP) with potent HTR2C antagonism may induce weight gain in susceptible individuals. Pharmacogenetic studies focusing either on the Cys23Ser polymorphism or on the −759C/T promoter polymorphism of the X‐linked HTR2C receptor gene revealed significant findings for the −759C/T polymorphism, however, no study has performed haplotype analyses for both polymorphisms.Methods: We analyzed three functional polymorphisms (Cys23Ser, −759C/T, and (GT)12–18/(CT) 4–5) of the HTR2C in 139 schizophrenic patients mainly treated with clozapine. Weight gain was assessed over a time course of 6–14 weeks (mean 8.2 weeks).Results: Single marker and haplotype analysis revealed no significant associations with AP‐induced weight gain. The haplotype Long‐C‐Ser was protective against weight gain, but the number of subjects available for that analysis was small.Conclusions: Our pilot study did not detect any significant haplotype conferring risk for antipsychotic‐induced weight gain although the statistical model took into account the X‐linked heterogeneity and did correct for confounding factors (i.e., ethnicity, medications, clinical response, time of assessment). Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and MortalityThe Journal of Clinical Psychiatry, 2005
- Pharmacogenomics in psychiatry: clinical issues to be consideredMolecular Psychiatry, 2005
- Serotonin receptor 2C (HTR2C) and schizophrenia: Examination of possible medication and genetic influences on expression levelsAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Antipsychotics and diabetes: Review of non-prospective dataThe British Journal of Psychiatry, 2004
- Pedigree disequilibrium tests for multilocus haplotypesGenetic Epidemiology, 2003
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- Novel 5′-regulatory region polymorphisms of the 5-HT2C receptor gene: association study with panic disorderInternational Journal of Neuropsychopharmacology, 2000
- Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature, 1995